The HA-1A monoclonal antibody for gram-negative sepsis

Raul J. Gazmuri; Carter Mecher; Max Harry Weil; Craig P. Tanio; Harold I. Feldman; J. Carlet; G. Offenstadt; C. Chastang; F. Doyon; C. Brun-Buisson; J. F. Dhainaut; B. Schlemmer; L. Gutmann; Gregory A. Schmidt; Harry B. Peled; S. Mackenzie; J. Kinsella; Lowell S. Young; Kenneth J. Gorelick; Jean Daniel Baumgartner; Didier Heumann; Michel Pierre Glauser; Elizabeth J. Ziegler; Charles J. Fisher; Charles L. Sprung; Craig R. Smith; Richard C. Straube; Jerald C. Sadoff; R. Phillip Dellinger; Sheldon M. Wolff

doi:10.1056/NEJM199107253250411

The HA-1A monoclonal antibody for gram-negative sepsis

Raul J. Gazmuri, Carter Mecher, Max Harry Weil, Craig P. Tanio, Harold I. Feldman, J. Carlet, G. Offenstadt, C. Chastang, F. Doyon, C. Brun-Buisson, J. F. Dhainaut, B. Schlemmer, L. Gutmann, Gregory A. Schmidt, Harry B. Peled, S. Mackenzie, J. Kinsella, Lowell S. Young, Kenneth J. Gorelick, Jean Daniel BaumgartnerDidier Heumann, Michel Pierre Glauser, Elizabeth J. Ziegler, Charles J. Fisher, Charles L. Sprung, Craig R. Smith, Richard C. Straube, Jerald C. Sadoff, R. Phillip Dellinger, Sheldon M. Wolff

Research output: Contribution to journal › Letter › peer-review

23 Scopus citations

Abstract

To the Editor: Ziegler and collaborators (Feb. 14 issue)¹ recently reported on an impressive reduction in 28-day mortality, from 49 percent to 30 percent, in a subgroup of patients who had bacteremia due to gram-negative bacilli. The patients were treated with human anti—lipid A monoclonal antibody early in the course after the onset of symptoms. Patients with sepsis or bacteremia caused by microorganisms other than gram-negative bacilli received no measurable benefit. These results prompted the investigators to recommend the therapy as routine treatment for patients with clinical signs of bacteremia, provided that a gram-negative organism was suspected as the cause.

Original language	English (US)
Pages (from-to)	279-283
Number of pages	5
Journal	New England Journal of Medicine
Volume	325
Issue number	4
DOIs	https://doi.org/10.1056/NEJM199107253250411
State	Published - Jul 25 1991
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM199107253250411

Cite this

Gazmuri, R. J., Mecher, C., Weil, M. H., Tanio, C. P., Feldman, H. I., Carlet, J., Offenstadt, G., Chastang, C., Doyon, F., Brun-Buisson, C., Dhainaut, J. F., Schlemmer, B., Gutmann, L., Schmidt, G. A., Peled, H. B., Mackenzie, S., Kinsella, J., Young, L. S., Gorelick, K. J., ... Wolff, S. M. (1991). The HA-1A monoclonal antibody for gram-negative sepsis. New England Journal of Medicine, 325(4), 279-283. https://doi.org/10.1056/NEJM199107253250411

Gazmuri, RJ, Mecher, C, Weil, MH, Tanio, CP, Feldman, HI, Carlet, J, Offenstadt, G, Chastang, C, Doyon, F, Brun-Buisson, C, Dhainaut, JF, Schlemmer, B, Gutmann, L, Schmidt, GA, Peled, HB, Mackenzie, S, Kinsella, J, Young, LS, Gorelick, KJ, Baumgartner, JD, Heumann, D, Glauser, MP, Ziegler, EJ, Fisher, CJ, Sprung, CL, Smith, CR, Straube, RC, Sadoff, JC, Dellinger, RP & Wolff, SM 1991, 'The HA-1A monoclonal antibody for gram-negative sepsis', New England Journal of Medicine, vol. 325, no. 4, pp. 279-283. https://doi.org/10.1056/NEJM199107253250411

@article{ba3865b5b35e408ab478047129cabb3c,

title = "The HA-1A monoclonal antibody for gram-negative sepsis",

abstract = "To the Editor: Ziegler and collaborators (Feb. 14 issue)1 recently reported on an impressive reduction in 28-day mortality, from 49 percent to 30 percent, in a subgroup of patients who had bacteremia due to gram-negative bacilli. The patients were treated with human anti—lipid A monoclonal antibody early in the course after the onset of symptoms. Patients with sepsis or bacteremia caused by microorganisms other than gram-negative bacilli received no measurable benefit. These results prompted the investigators to recommend the therapy as routine treatment for patients with clinical signs of bacteremia, provided that a gram-negative organism was suspected as the cause.",

author = "Gazmuri, {Raul J.} and Carter Mecher and Weil, {Max Harry} and Tanio, {Craig P.} and Feldman, {Harold I.} and J. Carlet and G. Offenstadt and C. Chastang and F. Doyon and C. Brun-Buisson and Dhainaut, {J. F.} and B. Schlemmer and L. Gutmann and Schmidt, {Gregory A.} and Peled, {Harry B.} and S. Mackenzie and J. Kinsella and Young, {Lowell S.} and Gorelick, {Kenneth J.} and Baumgartner, {Jean Daniel} and Didier Heumann and Glauser, {Michel Pierre} and Ziegler, {Elizabeth J.} and Fisher, {Charles J.} and Sprung, {Charles L.} and Smith, {Craig R.} and Straube, {Richard C.} and Sadoff, {Jerald C.} and Dellinger, {R. Phillip} and Wolff, {Sheldon M.}",

year = "1991",

month = jul,

day = "25",

doi = "10.1056/NEJM199107253250411",

language = "English (US)",

volume = "325",

pages = "279--283",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "4",

}

TY - JOUR

T1 - The HA-1A monoclonal antibody for gram-negative sepsis

AU - Gazmuri, Raul J.

AU - Mecher, Carter

AU - Weil, Max Harry

AU - Tanio, Craig P.

AU - Feldman, Harold I.

AU - Carlet, J.

AU - Offenstadt, G.

AU - Chastang, C.

AU - Doyon, F.

AU - Brun-Buisson, C.

AU - Dhainaut, J. F.

AU - Schlemmer, B.

AU - Gutmann, L.

AU - Schmidt, Gregory A.

AU - Peled, Harry B.

AU - Mackenzie, S.

AU - Kinsella, J.

AU - Young, Lowell S.

AU - Gorelick, Kenneth J.

AU - Baumgartner, Jean Daniel

AU - Heumann, Didier

AU - Glauser, Michel Pierre

AU - Ziegler, Elizabeth J.

AU - Fisher, Charles J.

AU - Sprung, Charles L.

AU - Smith, Craig R.

AU - Straube, Richard C.

AU - Sadoff, Jerald C.

AU - Dellinger, R. Phillip

AU - Wolff, Sheldon M.

PY - 1991/7/25

Y1 - 1991/7/25

N2 - To the Editor: Ziegler and collaborators (Feb. 14 issue)1 recently reported on an impressive reduction in 28-day mortality, from 49 percent to 30 percent, in a subgroup of patients who had bacteremia due to gram-negative bacilli. The patients were treated with human anti—lipid A monoclonal antibody early in the course after the onset of symptoms. Patients with sepsis or bacteremia caused by microorganisms other than gram-negative bacilli received no measurable benefit. These results prompted the investigators to recommend the therapy as routine treatment for patients with clinical signs of bacteremia, provided that a gram-negative organism was suspected as the cause.

AB - To the Editor: Ziegler and collaborators (Feb. 14 issue)1 recently reported on an impressive reduction in 28-day mortality, from 49 percent to 30 percent, in a subgroup of patients who had bacteremia due to gram-negative bacilli. The patients were treated with human anti—lipid A monoclonal antibody early in the course after the onset of symptoms. Patients with sepsis or bacteremia caused by microorganisms other than gram-negative bacilli received no measurable benefit. These results prompted the investigators to recommend the therapy as routine treatment for patients with clinical signs of bacteremia, provided that a gram-negative organism was suspected as the cause.

UR - http://www.scopus.com/inward/record.url?scp=0025900928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025900928&partnerID=8YFLogxK

U2 - 10.1056/NEJM199107253250411

DO - 10.1056/NEJM199107253250411

M3 - Letter

C2 - 2057029

AN - SCOPUS:0025900928

SN - 0028-4793

VL - 325

SP - 279

EP - 283

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 4

ER -

The HA-1A monoclonal antibody for gram-negative sepsis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this